Soleno Therapeutics shares surged over 20% after reports that Neurocrine Biosciences is in advanced talks to acquire the firm in a deal potentially worth $2.5 billion. Strong sales of its Prader-Willi drug Vykat XR and bullish retail sentiment have further fuelled investor optimism.